Delcath Systems, Inc. (DCTH) |
|
4.05 -0.06 (-1.46%)
|
09-29 16:00 |
|
Open: |
4.1 |
Pre. Close: |
4.11 |
|
High:
|
4.3399 |
Low:
|
4.03 |
|
Volume:
|
225,091 |
Market Cap:
|
62(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:54 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 5.77  One year: 6.47 |
| Support: |
Support1: 3.98 Support2: 3.31 |
| Resistance: |
Resistance1: 4.94 Resistance2: 5.53 |
| Pivot: |
4.35 |
| Moving Average: |
MA(5): 4.07 MA(20): 4.44
MA(100): 5.39 MA(250): 4.6  |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 7.4 %D(3): 7.9 |
| RSI: |
RSI(14): 39.5 |
| 52-week: |
High: 7.98 Low: 2.33 |
| Average Vol(K): |
3-Month: 2,372 (K) 10-Days: 275 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DCTH ] has closed above bottom band by 23.0%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.35 - 4.37 |
4.37 - 4.39 |
|
Low:
|
3.97 - 4 |
4 - 4.02 |
|
Close:
|
4.01 - 4.05 |
4.05 - 4.09 |
|
Company Description |
|
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York. |
Headline News |
Wed, 27 Sep 2023
Delcath Systems Reports Inducement Grants Under Nasdaq Listing ... - PR Newswire
Tue, 19 Sep 2023
Delcath Systems Inc (DCTH) Up 4.55% in Premarket Trading - InvestorsObserver
Sat, 09 Sep 2023
A Retrospective Comparative Study of Chemosat and SIRT ... - PR Newswire
Thu, 07 Sep 2023
Canaccord Genuity Maintains Delcath Systems (DCTH) Buy ... - Nasdaq
Tue, 05 Sep 2023
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023 - Yahoo Finance
Fri, 01 Sep 2023
Delcath Systems, Inc. Announces Additional $35 Million in Funding ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
-11 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
1.528e+007 (%) |
|
% Held by Institutions
|
1.059e+007 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
2.03e+006 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
226.7 |
|
Return on Equity (ttm)
|
-96.1 |
|
Qtrly Rev. Growth
|
696.8 |
|
Gross Profit (p.s.)
|
0.19 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-3.219e+007 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
-1.36 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
957710 |
|
Forward Dividend
|
530790 |
|
Dividend Yield
|
23647200% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
